Medicine & Life Sciences
Graft vs Host Disease
100%
Cell Transplantation
52%
Allogeneic Cells
43%
Primary Myelofibrosis
40%
National Institutes of Health (U.S.)
36%
Survival
31%
Transplantation
21%
Quality of Life
19%
Transplants
18%
Stem Cell Transplantation
17%
Mortality
16%
Polycythemia Vera
15%
Busulfan
15%
Bronchiolitis Obliterans
14%
Patient Reported Outcome Measures
13%
INCB018424
13%
Hematopoietic Stem Cell Transplantation
12%
Clinical Trials
11%
Skin
10%
Therapeutics
10%
Myelodysplastic Syndromes
10%
Multiple Myeloma
10%
Neoplasms
10%
Confidence Intervals
9%
Bone Marrow
9%
Acute Myeloid Leukemia
9%
fludarabine
9%
Homologous Transplantation
7%
Rituximab
7%
Steroids
7%
Lung
7%
RG7388
7%
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
6%
Melphalan
6%
Consensus
6%
Practice Guidelines
6%
trans-crotonin
6%
Comorbidity
6%
Recurrence
5%
Walk Test
5%
Karyotype
5%
Splenomegaly
5%
GATA2 Deficiency
5%
Bone Marrow Transplantation
5%
Amphiregulin
5%
venetoclax
5%
Sclerosis
5%
montelukast
5%
Fascia
5%
Janus Kinase Inhibitors
5%